NEONC TECHNOLOGIES HOLDINGS, INC.
NTHI evidence brief
What we can confirm
- BioSniper Score:
- 5.3 / 10
- Market Cap:
- $106.0M
- Lead Asset:
- neo212 (Phase 1/Phase 2)
What it means
What to watch
Prepared research question
What matters most for NTHI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NTHI
NeOnc Technologies Holdings, Inc. (NTHI) is a clinical-stage CNS oncology company developing therapies designed to overcome the blood-brain barrier, with lead programs NEO100 (intranasal delivery) and NEO212 (next-generation temozolomide) targeting brain cancers.
Key risk: Cash runway risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 4 clinical trials for NEONC TECHNOLOGIES HOLDINGS, INC..
NeOnc Technologies Holdings, Inc. (NTHI) is a clinical-stage CNS oncology company developing therapies designed to overcome the blood-brain barrier, with lead programs NEO100 (intranasal delivery) and NEO212 (next-generation temozolomide) targeting brain cancers.
- NEO100 met its Phase 2a primary endpoint with six-month PFS of 48.9% by RANO 2.0 versus a 20% benchmark [news · 2026-08-13].
- FDA provided CMC clearance for NEO212 to advance into a Phase 2 trial under the accelerated approval pathway [sec_mda · as of 2026-08-10].
- Cash & equivalents were $2.0M as of 2026-06-30, with zero revenue and a net loss of $14.2M [sec].
- The company has multiple Phase 2 trials ongoing for NEO100 and NEO212 across various glioma and meningioma indications [catalyst].
- Management has made insider stock purchases totaling over $800,000 in 2026, signaling conviction ahead of catalysts [news · 2026-04-14][news · 2026-05-05].
What works
- NEO100 achieved a positive Phase 2a readout with six-month PFS of 48.9% versus a 20% benchmark, suggesting potential clinical benefit [news · 2026-08-13].
- NEO212 received FDA CMC clearance to proceed into Phase 2 under the accelerated approval pathway, which could shorten time to market [sec_mda · as of 2026-08-10].
- Management has demonstrated financial commitment through insider stock purchases exceeding $800,000 in 2026 [news · 2026-04-14][news · 2026-05-05].
What to weigh
- The company had only $2.0M in cash as of 2026-06-30 and a negative shareholders' equity of -$18.5M, indicating a very tight cash runway [sec].
- Zero product revenue has been generated to date, and the company expects to incur significant expenses before any potential commercialization [sec_mda · as of 2026-03-31].
- Accumulated deficit and net loss of $14.2M in the latest reported period highlight ongoing financial strain [sec].
From the filings
Quoted directly from source documents.
NEO100 Phase 2a met primary endpoint with 48.9% six-month PFS
“NEO100 met its primary endpoint with six-month PFS of 48.9% by RANO 2.0 using Kaplan-Meier estimation versus a pre-specified 20% benchmark”
News · August 13, 2026
FDA CMC clearance for NEO212 Phase 2 under accelerated approval
“FDA provided chemistry, manufacturing and controls (CMC) clearance to advance NEO212 into a Phase 2 clinical trial and indicated that the NEO212 program may proceed under the FDA's accelerated approval pathway”
SEC MD&A · August 10, 2026
Catalyst timeline
- 2017-08-01 · Phase2_Start: NEO100 in recurrent/progressive Grade III/IV IDH1 mutant gliomas — An open-label Phase 1/2A dose escalation study of NEO100 in recurrent or progressive Grade III or Grade IV gliomas with IDH1 mutation.
- 2022-07-01 · Phase2_Start: NEO100 in high-grade meningioma — An open-label Phase 2 study of NEO100 in participants with residual, progressive or recurrent high-grade meningioma.
- 2023-11-01 · Phase2_Start: NEO212 in astrocytoma, glioblastoma, and brain metastasis — An open-label Phase 1/2 dose finding, safety and efficacy study of oral NEO212 in patients with astrocytoma IDH-mutant, glioblastoma IDH-wildtype or uncontrolled brain metastasis.
- 2026-01-01 · Phase1_Start: NEO100 intranasal Phase 1b — An open-label Phase 1b safety, dose-finding, brain tumor delivery, and pharmacokinetics study of intranasal NEO100.
Risks & what to watch (4)›
Key risks
- Cash runway risk — Only $2.0M cash as of 2026-06-30 with ongoing clinical expenses; may require near-term financing [sec].
- No revenue generation — Zero product revenue to date; all income depends on future regulatory approvals [sec_mda · as of 2026-03-31].
- Clinical trial execution risk — Multiple Phase 2 trials ongoing; failure to meet endpoints could delay or halt programs [catalyst].
- Negative shareholders' equity — Shareholders' equity of -$18.5M as of 2026-06-30 indicates accumulated losses exceed capital [sec].
What to watch
- NEO100 Phase 2a topline data release expected August 12, 2026 [news · 2026-08-11].
- NEO212 Phase 2 trial initiation and design details following FDA CMC clearance [sec_mda · as of 2026-08-10].
- Cash position updates and potential financing or partnership announcements in upcoming quarterly reports [sec].
- Insider buying activity as a signal of management confidence ahead of catalysts [news · 2026-04-14][news · 2026-05-05].
Sources: Catalysts · News · SEC MD&A · Generated September 30, 2026 · How we verify sources →
Run NEONC TECHNOLOGIES HOLDINGS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NEONC TECHNOLOGIES HOLDINGS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$14M
Lead: Phase 1/Phase 2
1 candidate
No upcoming catalysts tracked
10 buys · 0 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of Apr 20, 2026- % of float
- 2.1%
- Days to cover
- 7.9
- Shares short
- 289,781
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NTHI short interestGovernance
Frequently asked questions
What is the AI investment thesis for NEONC TECHNOLOGIES HOLDINGS, INC.?
NeOnc Technologies Holdings, Inc. (NTHI) is a clinical-stage CNS oncology company developing therapies designed to overcome the blood-brain barrier, with lead programs NEO100 (intranasal delivery) and NEO212 (next-generation temozolomide) targeting brain cancers.
What is NEONC TECHNOLOGIES HOLDINGS, INC.'s lead drug candidate?
NEONC TECHNOLOGIES HOLDINGS, INC.'s most advanced tracked candidate is neo212 (Phase 1/Phase 2) for Diffuse Astrocytoma, IDH-Mutant.
Who is the CEO of NEONC TECHNOLOGIES HOLDINGS, INC.?
Mr. Amir Farrokh Heshmatpour is the chief executive officer of NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI).
Where is NEONC TECHNOLOGIES HOLDINGS, INC. headquartered?
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) is headquartered in Calabasas, CA, United States.
What therapeutic areas does NEONC TECHNOLOGIES HOLDINGS, INC. focus on?
NEONC TECHNOLOGIES HOLDINGS, INC. develops therapies across Oncology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.